Les traitements du rétrécissement aortique calcifié : place du TAVI

Calcified aortic valve disease (CAVD) is the most prevalent valve disease in adult affecting an estimated 5% of patients aged more than 65 years. Its prevalence is projected to doble or triple in the 50 next years due to the aging population. CAVD is characterized by a progressive thickening and calcification of the aortic valve limiting its opening. Untreated, severe symptomatic patients, have a poor prognosis, with as many as 80% of patients dying within 2 years. Surgical aortic valve replacement (AVR) was during several years the only possible treatment. However, more than 30% of the patients are not operable. For these patients, less invasive technics have been developped using cardiac cathetherization, including percutaneous transluminal balloon catheter aortic valvuloplasty [1] and in 2002, Transcatheter Aortic Valve Implantation (TAVI) [2] invented by Alain Cribier and our team.